evolution of patients with aids after cart: clinical and laboratory evolution of patients with aids after 48 weeks of antiretroviral treatment

Clicks: 416
ID: 218230
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #4 of 173 articles by views in 2017 12th international conference for internet technology and secured transactions, icitst 2017

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 173 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
SUMMARY Combination Antiretroviral Therapy (cART) aims to inhibit viral replication, delay immunodeficiency progression and improve survival in AIDS patients. The objective of this study was to compare two different schemes of cART, based on plasma viral load (VL) and CD4+ T lymphocyte count, during 48 weeks of treatment. For this purpose, 472 medical charts of a Specialized Outpatient Service were reviewed from 1998 to 2005. Out of these, 58 AIDS patients who had received a triple drug scheme as the initial treatment were included in the study and two groups were formed: Group 1 (G1): 47 individuals treated with two nucleoside reverse-transcriptase inhibitors (NRTI) and one non-nucleoside reverse-transcriptase inhibitor; Group 2 (G2): 11 patients treated with two NRTI and one protease inhibitor. In G1 and G2, 53.2% and 81.8% respectively were patients with an AIDS-defining disease. The T CD4+ lymphocyte count increased progressively up until the 24th week of treatment in all patients, while VL became undetectable in 68.1% of G1 and in 63.6% of G2. The study concluded that the evolutions of laboratory tests were similar in the two treatment groups and that both presented a favorable clinical evolution.
Reference Key
fukumoto2013revistaevolution Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Ana Esther Carvalho Gomes Fukumoto;Cristiano Claudino Oliveira;Karen Ingrid Tasca;Lenice do Rosario de Souza
Journal 2017 12th international conference for internet technology and secured transactions, icitst 2017
Year 2013
DOI
10.1590/S0036-46652013000400008
URL
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652013000400267&lng=en&tlng=en
Keywords
hiv/aids antiretroviral therapy tropical medicine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.